



Verisana LAB · c/o Brian Kalish · 818 N Quincy Street ·
Unit 806 · Arlington VA 22203

Jane Smith
Sample Street
Anytown

**Surname,
First name** Smith, Jane

DOB 01/01/1990

Sex female

Laboratory # 10000002

Date collected 01/01/2019

Date received 01/01/2019



Report date 01/03/2019

Laboratory report

Enclosed you will find the results of your laboratory examination. In addition to your results you will also receive a brief summary of the correlating effects, regarding the tested parameters. These are compiled without any knowledge on the clinical background and as such, may only be used as an interpretation aid. In case of health problems, please consult a doctor or practitioner for medical treatment and accompaniment for making the best decisions for your health. We explicitly warn against beginning, suspending or changing any medication or therapy without consulting your doctor or practitioner.

Test: Estrogen Dominance

Sample material: saliva

Analyte	Result	Reference range	Result
Estradiol	3,4 pg/ml	1st Cycle phase: 0,2-10,4 pg/ml Ovulation: 5,8-21,2 pg/ml 2nd Cycle phase: 0,8-10,8 pg/ml Contraceptives: 0,5-2,2 pg/ml Postmenopausal: < 4,3 pg/ml Estradiol plaster (0,05mg): 0,8-2 pg/ml Oral Estradiol: 1,2-3,9 pg/ml Topical Estradiol (0,5-1 mg): 2,9-35,5 pg/ml	
Progesterone	150,0 pg/ml	1st Cycle phase: 50-100 pg/mL Ovulation: 100-150 pg/ml 2nd Cycle phase: 100-450 pg/ml Postmenopausal: 12-50 pg/ml Contraceptives: 12-50 pg/ml	

Verisana LAB

c/o Brian Kalish
818 N Quincy Street
Unit 806
Arlington VA 22203

Email: contact@verisana.com
Phone: (703) 722 6067
www.verisana.com



Surname, First name	DOB	Laboratory #	Report date
Smith, Jane	01/01/1990	10000002	01/03/2019

Synthetic HET: 12-51 pg/ml
 Progesterone, oral (100-300 mg): 100-500 pg/ml
 Progesterone creme/gel (10-30 mg): 200-3000 pg/ml

Progesterone/Estradiol -Ratio 38,2

The progesterone/estradiol quotient is a quotient which measures the estrogen dominance. The reference refers to a progesterone/ estradiol ratio of 100:1. The quotient should be at least 100. A lower quotient indicated an estrogen dominance.



The estradiol level is increased. Estradiol is the most effective estrogen of the estrogen hormone family and is the female fertility hormone. In the case of fertile women, it has an effect on the maturation of the egg cells and is involved in the development of the lining of the womb in the first half of the cycle. A normal menstrual cycle is followed by a typical monthly profile, with a clear increase towards the ovulation. A rise in the estradiol values is often accompanied by symptoms such as sensitive breasts and water retention.

The progesterone level is increased. An increased concentration of progesterone can, for example, be measured during a progesterone therapy. Increased values can, during a progesterone therapy, lead to drowsiness, a slight dizziness, constipation, increased cortisol levels or symptoms of a progesterone deficiency (water retention, depressive moods, sensitive breasts).

The progesterone/estradiol quotient is reduced by 38,2:1. Therefore the progesterone is decreased in relation to the estradiol. This is known as a so-called estrogen dominance. An estrogen dominance does not necessarily mean an excess of estrogen or progesterone. It describes an imbalance between estrogen and its counterpart progesterone. The body reacts as though too much estrogen is present. This can even be the case with an estrogen deficiency, as the relative ratio between the two is decisive. The progesterone/estradiol quotient can also be helpful by indications for a relative estrogen dominance, if the progesterone and estrogen values are within the normal range. Hint: With the presently existing standard values, a progesterone/estradiol ratio of 100:1 is rarely achievable. The current standard range has probably not been estimated high enough. The calculation of the quotient was done in the unit mol.

Yours sincerely
 Your laboratory team



Surname,
First name
Smith, Jane

DOB

01/01/1990

Laboratory #

10000002

Report date

01/03/2019

Verisana LAB

c/o Brian Kalish
818 N Quincy Street
Unit 806
Arlington VA 22203

Email: contact@verisana.com
Phone: (703) 722 6067
www.verisana.com